Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
We must try to make the health care system more accessible for people with disabilities
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Subscribe To Our Newsletter & Stay Updated
